Menzel S - Search Results

1

Novel biologics targeting the P2X7 ion channel.

Koch-Nolte F, Eichhoff A, Pinto-Espinoza C, Schwarz N, Schäfer T, Menzel S, Haag F, Demeules M, Gondé H, Adriouch S. Koch-Nolte F, et al. Among authors: menzel s. Curr Opin Pharmacol. 2019 Aug;47:110-118. doi: 10.1016/j.coph.2019.03.001. Epub 2019 Apr 12. Curr Opin Pharmacol. 2019. PMID: 30986625 Review.

2

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.

Menzel S, Schwarz N, Haag F, Koch-Nolte F. Menzel S, et al. Front Pharmacol. 2018 Mar 27;9:266. doi: 10.3389/fphar.2018.00266. eCollection 2018. Front Pharmacol. 2018. PMID: 29636685 Free PMC article. Review.

3

Development of Antibody and Nanobody Tools for P2X7.

Stähler T, Danquah W, Demeules M, Gondé H, Hardet R, Haag F, Adriouch S, Koch-Nolte F, Menzel S. Stähler T, et al. Among authors: menzel s. Methods Mol Biol. 2022;2510:99-127. doi: 10.1007/978-1-0716-2384-8_6. Methods Mol Biol. 2022. PMID: 35776322

4

The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs.

Menzel S, Rissiek B, Haag F, Goldbaum FA, Koch-Nolte F. Menzel S, et al. FEBS J. 2013 Aug;280(15):3543-50. doi: 10.1111/febs.12313. Epub 2013 Jun 14. FEBS J. 2013. PMID: 23627412 Free article. Review.

5

Nucleotide-Induced Membrane-Proximal Proteolysis Controls the Substrate Specificity of T Cell Ecto-ADP-Ribosyltransferase ARTC2.2.

Menzel S, Rissiek B, Bannas P, Jakoby T, Miksiewicz M, Schwarz N, Nissen M, Haag F, Tholey A, Koch-Nolte F. Menzel S, et al. J Immunol. 2015 Sep 1;195(5):2057-66. doi: 10.4049/jimmunol.1401677. Epub 2015 Jul 24. J Immunol. 2015. PMID: 26209623

6

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.

Eden T, Menzel S, Wesolowski J, Bergmann P, Nissen M, Dubberke G, Seyfried F, Albrecht B, Haag F, Koch-Nolte F. Eden T, et al. Among authors: menzel s. Front Immunol. 2018 Jan 23;8:1989. doi: 10.3389/fimmu.2017.01989. eCollection 2017. Front Immunol. 2018. PMID: 29410663 Free PMC article.

7

Monitoring Expression and Enzyme Activity of Ecto-ARTCs.

Menzel S, Adriouch S, Bannas P, Haag F, Koch-Nolte F. Menzel S, et al. Methods Mol Biol. 2018;1813:167-186. doi: 10.1007/978-1-4939-8588-3_11. Methods Mol Biol. 2018. PMID: 30097867

8

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD⁺ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells.

Baum N, Fliegert R, Bauche A, Hambach J, Menzel S, Haag F, Bannas P, Koch-Nolte F. Baum N, et al. Among authors: menzel s. Cancers (Basel). 2020 Dec 30;13(1):76. doi: 10.3390/cancers13010076. Cancers (Basel). 2020. PMID: 33396591 Free PMC article.

9

Ecto-ADP-ribosyltransferase ARTC2.1 functionally modulates FcγR1 and FcγR2B on murine microglia.

Rissiek B, Menzel S, Leutert M, Cordes M, Behr S, Jank L, Ludewig P, Gelderblom M, Rissiek A, Adriouch S, Haag F, Hottiger MO, Koch-Nolte F, Magnus T. Rissiek B, et al. Among authors: menzel s. Sci Rep. 2017 Nov 28;7(1):16477. doi: 10.1038/s41598-017-16613-w. Sci Rep. 2017. PMID: 29184112 Free PMC article.

10

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.

Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Röckendorf J, Menzel S, Albrecht B, Haag F, Stortelers C, Bannas P, Koch-Nolte F. Schütze K, et al. Among authors: menzel s. Front Immunol. 2018 Nov 19;9:2553. doi: 10.3389/fimmu.2018.02553. eCollection 2018. Front Immunol. 2018. PMID: 30524421 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

282 results

Search Page

Filters